whereas content in Step 2 CK aims to measure knowledge of clinical principles required for the supervised practice of medicine. 4 The objective of this study was to assess use of
Step 2 CK scores in resident selection in US dermatology residency programs. Table 1) . Among respondents whose programs required or used
Step 2 scores, 12.9% (9 of 75) applied a minimum cutoff score (mean, 226; range, 210-235) . Respondents in programs that required Step 2 reported using it to compare applicants objectively (4 of 5 respondents [80%]) ( Table 2) . Respondents in programs which reported using but not requiring Step 2 scores generally wanted to measure improvement on Step 2 relative to Step 1 (42 of 65 respondents [65%]). The primary reason for not requiring or using Step 2 was insufficient value in predicting clinical performance (4 of 5 respondents [80%]).
Seventeen of 75 respondents (23%) offered additional comments. The most common themes included the predictive value of Step 2 in future examination performance (5 of 17 respondents [29%]) and clinical performance (3 of 17 respondents [18%]), preference for roughly consistent performance on Step 1 and Step 2 or improvement on Step 2 if Step 1 was below average (5 of 17 respondents [29%]), and disapproval or concern when applicants delay Step 2 (3 of 17 respondents [18%]).
Discussion | Our findings suggest that
Step 2 CK scores are widely used but not commonly required in the selection of dermatology resident applicants. Moreover, our study indicates that Step 2 for different purposes (eg, evaluation of improvement relative to Step 1 score or objective comparison between applicants). These findings are limited by the degree to which survey responses reflect actual selection criteria and the degree to which they represent all dermatology residency programs. Because dermatology residency applicants typically apply to 60 to 80 programs 6 and are therefore likely to apply to at least one of the programs that require or prefer
Step 2 scores, advisors to dermatology applicants should encourage them to take Step 2 before applying. Those applicants with below-average Step 1 scores might especially benefit.
OBSERVATION

Secukinumab-Induced Psoriasiform Eruption
Tumor necrosis factor (TNF) and interleukin (IL)-12/23 (ustekinumab) blockade are highly effective treatments for many autoimmune conditions including psoriasis, but rarely these agents can paradoxically induce psoriasiform eruptions. 1-4 Interestingly, ustekinumab has been shown to control TNF inhibitor-induced psoriasis, 2 and TNF inhibitors have been shown to control ustekinumab-induced psoriasis, 4 supporting the hypothesis of multiple pathways in psoriasis with one or the other being most important in an individual patient. If this is true, then if an individual experiences disease flares with one class of biological agent, a treatment response may be achieved with another class. To our knowledge, similar paradoxical adverse psoriasiform reactions have not been reported with IL-17A inhibition. We wish to report a case of secukinumab (anti-IL-17A monoclonal antibody) treatment-emergent psoriasiform eruption involving the fingertips and nails.
Report of a Case | A 61-year-old woman had severe, recalcitrant psoriasis vulgaris that failed to respond to therapy with topical agents, UV light, methotrexate, acitretin, and adalimumab but cleared completely within 2 months of commencing secukinumab treatment. However, after 3 months' treatment with secukinumab, she developed severe, disabling fingernail dystrophy and distal onychopathy in previously normal nails (Figure 1) . Her toes were unaffected. Differential diagnoses included fingertip and fingernail psoriasis, acrodermatitis continua of Hallopeau, and Candida infection.
There was no growth on repeated nail clipping culture and no response to a 6-week course of oral fluconazole, suggesting that Candida infection was unlikely. Her fingertips and fingernails did not respond to 6 weeks of combined topical clobetasol ointment under occlusion and subcutaneous methotrexate, 25 mg/wk. Secukinumab treatment was discontinued after 6 months of treatment, but secukinumab cessation and ongoing treatment with topical clobetasol and subcuta- 
